• ABOUT ELITE
    • Overview
    • Our Facility
    • Management & Key Employees
    • Our Board
    • Careers
  • PRODUCTS
  • PIPELINE
    • Generic
    • Branded
  • TECHNOLOGY
    • Technology Overview
    • How It Works
    • One Bead System
    • Two Bead System
  • INVESTOR RELATIONS
    • Press Releases
    • Events & Presentations
    • SEC Filings
    • Shareholder Meeting
    • Governance Documents
    • Investor Contacts
    • Email Alerts
logo image
HOME | CAREERS | CONTACT | NEWS |
Share
Skip to content
  • About Elite
    • Overview
    • Management & Key Employees
    • Our Board
    • Careers
  • Products
  • Pipeline
    • Generic
    • Branded
  • Technology
    • Technology Overview
    • How It Works
    • One Bead System
    • Two Bead System
  • Investor Relations
    • Press Releases
    • Events & Presentations
    • SEC Filings
    • Shareholder Meeting
    • Governance Documents
    • Investor Contacts
    • Email Alerts
    • Investor Relations
    • Press Releases
    • Events &
      Presentations
    • SEC Filings
    • Shareholder
      Meeting
    • Governance
      Documents
    • Investor Contacts
    • Email Alerts

Press Releases
Select:
Apr 30, 2025
Elite Pharmaceuticals Announces Commercial Launch of Oxycodone and Acetaminophen Tablets
Mar 03, 2025
Elite Pharmaceuticals, Inc. Announces First Shipment of Product from New Facility and Packaging Line
Feb 13, 2025
Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2025 ended December 31, 2024 and Provides Conference Call Information
Feb 10, 2025
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2025 Financial Results on February 14, 2025
Dec 26, 2024
Elite Pharmaceuticals Announces Commercial Launch of Generic Vyvanse®
Dec 02, 2024
Elite Pharmaceuticals Announces Commercial Launch of Acetaminophen and Hydrocodone Tablets
Nov 18, 2024
Elite Pharmaceuticals Receives FDA Approval for Generic Vyvanse
Nov 14, 2024
Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2025 Ended September 30, 2024 and Provides Conference Call Information
Nov 07, 2024
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2025 Financial Results on November 15, 2024
Oct 10, 2024
Elite Pharmaceuticals' Generic Adderall® Receives Marketing Approval from the Israeli Ministry of Health
   1    2   3   4   5   6 
 <<   <   >   >> 
  • Site Map   |  Privacy  |  Terms Of Use
Copyright © Elite Pharmaceuticals Inc. | All Rights Reserved.
ART™: Abuse-Resistant Technology for a safer healthier you.
Back to top

Privacy
Resize Viewer - Reduce Resize Viewer - Expand Close window